Table 1_Evaluation of the protective efficacy of a recombinant adenovirus-vectored SARS-CoV-2 vaccine candidate for veterinary use.docx

Since 2019, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed a global health threat. Its high transmissibility and cross-species infectivity have disrupted public health systems and worldwide economies, with companion and agricultural animals, like cats and minks, showing high susceptibility. ​This study evaluated rAd5-S6P, a recombinant vaccine using an adenovirus type 5 vector expressing a modified SARS-CoV-2 spike protein, in murine, feline, and mink models. Results demonstrated that rAd5-S6P elicited a robust humoral immune response when administered via intramuscular, intranasal, and oral routes, which conferred complete protection in mice. In feline and mink models, immunization with rAd-S6P resulted in significantly reduced viral shedding after high-dose SARS-CoV-2 challenge, and no infectious virus was detected in any of the examined organs of minks. Collectively, rAd5-S6P exhibited protective efficacy across species, supporting its translational potential as a veterinary vaccine. These findings provide critical evidence for animal vaccination strategies to control SARS-CoV-2 circulation and reduce zoonotic transmission risks.

自2019年以来，严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）已对全球公共卫生构成威胁。其高传播性与跨物种感染能力已严重扰乱全球公共卫生体系与世界经济，猫、貂等伴侣动物与畜禽均表现出极高易感性。本研究在鼠类、猫科及貂类动物模型中，评价了以5型腺病毒为载体、表达经修饰SARS-CoV-2刺突蛋白的重组疫苗rAd5-S6P。实验结果显示，通过肌内、鼻内与口服途径接种rAd5-S6P，可诱导强烈的体液免疫应答，并对小鼠实现完全保护。在猫科与貂类动物模型中，经rAd-S6P免疫的个体在高剂量SARS-CoV-2攻毒后，病毒排毒量显著降低；且在所有检测的貂类脏器中均未检出感染性病毒。综上，rAd5-S6P在不同物种中均展现出良好的保护效力，支持其作为兽用疫苗的转化应用潜力。本研究结果为通过动物免疫策略控制SARS-CoV-2的传播循环、降低人畜共患传播风险提供了关键证据。